HomeCompareKESPF vs JNJ

KESPF vs JNJ: Dividend Comparison 2026

KESPF yields 2500.00% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KESPF wins by $80609755877.34M in total portfolio value
10 years
KESPF
KESPF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full KESPF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — KESPF vs JNJ

📍 KESPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKESPFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KESPF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KESPF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KESPF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, KESPF beats the other by $63,520,143,069,575,950.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KESPF + JNJ for your $10,000?

KESPF: 50%JNJ: 50%
100% JNJ50/50100% KESPF
Portfolio after 10yr
$40304877938.70M
Annual income
$37,364,790,040,931,720.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

KESPF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KESPF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKESPFJNJ
Forward yield2500.00%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$80609755877.37M$30.3K
Annual income after 10y$74,729,580,081,858,750.00$4,689.40
Total dividends collected$80198875900.38M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: KESPF vs JNJ ($10,000, DRIP)

YearKESPF PortfolioKESPF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$260,700$250,000.00$10,592$272.30+$250.1KKESPF
2$6,370,070$6,091,121.50$11,289$357.73+$6.36MKESPF
3$145,912,632$139,096,656.81$12,123$472.89+$145.90MKESPF
4$3,133,830,814$2,977,704,297.75$13,141$629.86+$3133.82MKESPF
5$63,122,812,060$59,769,613,088.96$14,408$846.81+$63122.80MKESPF
6$1,192,683,724,131$1,125,142,315,226.76$16,021$1,151.60+$1192683.71MKESPF
7$21,144,559,711,004$19,868,388,126,183.19$18,122$1,588.22+$21144559.69MKESPF
8$351,818,906,448,043$329,194,227,557,269.44$20,930$2,228.20+$351818906.43MKESPF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$24,792$3,191.91+$5495491397.65MKESPF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$30,274$4,689.40+$80609755877.34MKESPF

KESPF vs JNJ: Complete Analysis 2026

KESPFStock

Kleos Space S.A., together with its subsidiaries, engages in the development of the space enabled, activity-based intelligence, and data-as-a-service (DaaS) products in Luxembourg and internationally. It offers activity-based intelligence and geolocation-as-a-service to guard borders, protect assets, and save lives. The company also provides Kleos Scouting Mission, a space satellite system; and researches and develops radio frequency (RF) geolocation and signal analysis techniques, as well as data science techniques, including machine learning, satellite technologies, and data processing methodologies solutions. It offers DaaS products to defence and security intelligence surveillance and reconnaissance markets, as well as to perform the tests on the equipment for launching low earth orbit (LEO) nano-satellite earth observation. The company was formerly known as Kleos Space S.à r.l. Kleos Space S.A. was incorporated in 2017 and is based in Luxembourg, Luxembourg.

Full KESPF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this KESPF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KESPF vs SCHDKESPF vs JEPIKESPF vs OKESPF vs KOKESPF vs MAINKESPF vs ABBVKESPF vs MRKKESPF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.